Jonas Hannestad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jonas Hannestad has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Nicole DellaGioia
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
5 shared publicationsBrian Pittman
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
3 shared publicationsRichard E. Carson
Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA
3 shared publicationsJean-Dominique Gallezot
Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA
2 shared publicationsKeunpoong Lim
Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA
2 shared publications- Zubin Bhagwagar
Yale University
2 shared publications
Latest Publications
- 29 April 2018
- Published by Springer Nature
- Vol. 1781, 287-307
PET Imaging in Psychoneuroimmunology Research
Positron-emission tomography (PET) imaging is a valuable research tool that enables in vivo quantification of molecular targets in the brain or of a physiologic process. PET imaging can be combined with various experimental and clinical model systems that are commonly used in psychoneuroimmunology research. As PET imaging can be used in animals and humans, promising results can therefore often be translated from an animal model to human disease.
- 29 April 2018
- Published by Springer Nature
- Vol. 1781, 287-307
PET Imaging in Psychoneuroimmunology Research
Positron-emission tomography (PET) imaging is a valuable research tool that enables in vivo quantification of molecular targets in the brain or of a physiologic process. PET imaging can be combined with various experimental and clinical model systems that are commonly used in psychoneuroimmunology research. As PET imaging can be used in animals and humans, promising results can therefore often be translated from an animal model to human disease.
- 1 October 2013
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 33, 131-138
The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study
- 1 October 2013
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 33, 131-138
The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study
- 1 October 2012
- Published by Elsevier in NeuroImage
- Vol. 63 (1) , 232-239
Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates
- 1 October 2012
- Published by Elsevier in NeuroImage
- Vol. 63 (1) , 232-239
Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates
- 21 September 2012
- Published by Springer Nature
- p. 95-132
Neuroimaging and Clinical Studies on Brain–Immune Interactions
- 21 September 2012
- Published by Springer Nature
- p. 95-132
Neuroimaging and Clinical Studies on Brain–Immune Interactions
- 24 July 2012
- Published by Springer Nature
- Vol. 934, 325-353
The Application of PET Imaging in Psychoneuroimmunology Research
Positron emission tomography (PET) imaging is a research tool that allows in vivo measurements of brain metabolism and specific target molecules. PET imaging can be used to measure these brain variables in a variety of species, including human and non-human primates, and rodents. PET imaging can therefore be combined with various experimental and clinical model systems that are commonly used in psychoneuroimmunology research.
- 24 July 2012
- Published by Springer Nature
- Vol. 934, 325-353
The Application of PET Imaging in Psychoneuroimmunology Research
Positron emission tomography (PET) imaging is a research tool that allows in vivo measurements of brain metabolism and specific target molecules. PET imaging can be used to measure these brain variables in a variety of species, including human and non-human primates, and rodents. PET imaging can therefore be combined with various experimental and clinical model systems that are commonly used in psychoneuroimmunology research.
- Open Access
- 13 March 2012
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (4) , 601-607
Glucose Metabolism in the Insula and Cingulate Is Affected by Systemic Inflammation in Humans
Depression is associated with systemic inflammation, and the systemic inflammation caused by endotoxin administration elicits mild depressive symptoms such as fatigue and reduced interest. The neural correlates of depressive symptoms that result from systemic inflammation are poorly defined. The aim of this study was to use 18F-FDG PET to identify brain regions involved in the response to endotoxin administration in humans. Methods: Nine healthy subjects received double-blind endotoxin (0.8 ng/kg) and placebo on different days. 18F-FDG PET was used to measure differences in the cerebral metabolic rate of glucose in the following regions of interest: insula, cingulate, and amygdala. Serum levels of tumor necrosis factor-α and interleukin-6 were used to gauge the systemic inflammatory response, and depressive symptoms were measured with the Montgomery-Åsberg Depression Rating Scale and other scales. Results: Endotoxin administration was associated with an increase in Montgomery-Åsberg Depression Rating Scale, increased fatigue, reduced social interest, increased levels of inflammatory cytokines, higher normalized glucose metabolism (NGM) in the insula, and, at a trend level, lower NGM in the cingulate. Secondary analyses of insula and cingulate subregions indicated that these changes were driven by the right anterior insula and the right anterior cingulate. There was a negative correlation between peak cytokine levels and change in social interest and between peak cytokine levels and change in insula NGM. There was a positive correlation between the change in NGM in the insula and change in social interest. Conclusion: Systemic inflammation in humans causes an increase in depressive symptoms and concurrent changes in glucose metabolism in the insula and cingulate—brain regions that are involved in interoception, positive emotionality, and motivation.
- 13 March 2012
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (4) , 601-607
Open AccessGlucose Metabolism in the Insula and Cingulate Is Affected by Systemic Inflammation in Humans
Depression is associated with systemic inflammation, and the systemic inflammation caused by endotoxin administration elicits mild depressive symptoms such as fatigue and reduced interest. The neural correlates of depressive symptoms that result from systemic inflammation are poorly defined. The aim of this study was to use 18F-FDG PET to identify brain regions involved in the response to endotoxin administration in humans. Methods: Nine healthy subjects received double-blind endotoxin (0.8 ng/kg) and placebo on different days. 18F-FDG PET was used to measure differences in the cerebral metabolic rate of glucose in the following regions of interest: insula, cingulate, and amygdala. Serum levels of tumor necrosis factor-α and interleukin-6 were used to gauge the systemic inflammatory response, and depressive symptoms were measured with the Montgomery-Åsberg Depression Rating Scale and other scales. Results: Endotoxin administration was associated with an increase in Montgomery-Åsberg Depression Rating Scale, increased fatigue, reduced social interest, increased levels of inflammatory cytokines, higher normalized glucose metabolism (NGM) in the insula, and, at a trend level, lower NGM in the cingulate. Secondary analyses of insula and cingulate subregions indicated that these changes were driven by the right anterior insula and the right anterior cingulate. There was a negative correlation between peak cytokine levels and change in social interest and between peak cytokine levels and change in insula NGM. There was a positive correlation between the change in NGM in the insula and change in social interest. Conclusion: Systemic inflammation in humans causes an increase in depressive symptoms and concurrent changes in glucose metabolism in the insula and cingulate—brain regions that are involved in interoception, positive emotionality, and motivation.
- Top Cited PapersOpen Access
- 27 July 2011
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 36 (12) , 2452-2459
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Serum levels of inflammatory cytokines, for example, tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1 beta (IL-1β), are elevated in subjects with major depressive disorder (MDD). The reason why this occurs is unclear. Elevated levels of inflammatory cytokines could be a result of brain dysfunction in MDD. It is also possible that inflammatory cytokines contribute to depressive symptoms in MDD. If the first assumption is correct, one would expect levels to normalize with resolution of the depressive episode after treatment. Several studies have measured changes in cytokine levels during antidepressant treatment; however, the results vary. The purpose of this study was to pool all available data on changes in serum levels of TNFα, IL-6, and IL-1β during antidepressant treatment to determine whether these levels change. Studies were included if they used an approved pharmacological treatment for depression, patients had a diagnosis of MDD, and serum levels of TNFα, IL-6, and/or IL-1β were measured before and after treatment. Twenty-two studies fulfilled these criteria. Meta-analysis of these studies showed that, overall, while pharmacological antidepressant treatment reduced depressive symptoms, it did not reduce serum levels of TNFα. On the other hand, antidepressant treatment did reduce levels of IL-1β and possibly those of IL-6. Stratified subgroup analysis by class of antidepressant indicated that serotonin reuptake inhibitors may reduce levels of IL-6 and TNFα. Other antidepressants, while efficacious for depressive symptoms, did not appear to reduce cytokine levels. These results argue against the notion that resolution of a depressive episode is associated with normalization of levels of circulating inflammatory cytokines; however, the results are consistent with the possibility that inflammatory cytokines contribute to depressive symptoms and that antidepressants block the effects of inflammatory cytokines on the brain.
- 27 July 2011
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 36 (12) , 2452-2459
Top Cited PapersOpen AccessThe Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Serum levels of inflammatory cytokines, for example, tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1 beta (IL-1β), are elevated in subjects with major depressive disorder (MDD). The reason why this occurs is unclear. Elevated levels of inflammatory cytokines could be a result of brain dysfunction in MDD. It is also possible that inflammatory cytokines contribute to depressive symptoms in MDD. If the first assumption is correct, one would expect levels to normalize with resolution of the depressive episode after treatment. Several studies have measured changes in cytokine levels during antidepressant treatment; however, the results vary. The purpose of this study was to pool all available data on changes in serum levels of TNFα, IL-6, and IL-1β during antidepressant treatment to determine whether these levels change. Studies were included if they used an approved pharmacological treatment for depression, patients had a diagnosis of MDD, and serum levels of TNFα, IL-6, and/or IL-1β were measured before and after treatment. Twenty-two studies fulfilled these criteria. Meta-analysis of these studies showed that, overall, while pharmacological antidepressant treatment reduced depressive symptoms, it did not reduce serum levels of TNFα. On the other hand, antidepressant treatment did reduce levels of IL-1β and possibly those of IL-6. Stratified subgroup analysis by class of antidepressant indicated that serotonin reuptake inhibitors may reduce levels of IL-6 and TNFα. Other antidepressants, while efficacious for depressive symptoms, did not appear to reduce cytokine levels. These results argue against the notion that resolution of a depressive episode is associated with normalization of levels of circulating inflammatory cytokines; however, the results are consistent with the possibility that inflammatory cytokines contribute to depressive symptoms and that antidepressants block the effects of inflammatory cytokines on the brain.
- 1 February 2011
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 25 (2) , 256-259
Citalopram reduces endotoxin-induced fatigue
- 1 February 2011
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 25 (2) , 256-259
Citalopram reduces endotoxin-induced fatigue
- 1 January 2010
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 34 (1) , 130-143
A critical review of human endotoxin administration as an experimental paradigm of depression
- 1 January 2010
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 34 (1) , 130-143
A critical review of human endotoxin administration as an experimental paradigm of depression
- 1 June 2008
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 13 (6) , 501-510
Inflammation, Glutamate, and Glia in Depression:A Literature Review
Multiple lines of evidence suggest that inflammation and glutamate dysfunction contribute to the pathophysiology of depression. In this review we provide an overview of how these two systems may interact. Excess levels of inflammatory mediators occur in a subgroup of depressed patients. Studies of acute experimental activation of the immune system with endotoxin and of chronic activation during interferon-α treatment show that inflammation can cause depression. Peripheral inflammation leads to microglial activation which could interfere with excitatory amino acid metabolism leading to inappropriate glutamate receptor activation. Loss of astroglia, a feature of depression, upsets the balance of anti- and pro-inflammatory mediators and further impairs the removal of excitatory amino acids. Microglia activated by excess inflammation, astroglial loss, and inappropriate glutamate receptor activation ultimately disrupt the delicate balance of neuroprotective versus neurotoxic effects in the brain, potentially leading to depression.
- 1 June 2008
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 13 (6) , 501-510
Inflammation, Glutamate, and Glia in Depression:A Literature Review
Multiple lines of evidence suggest that inflammation and glutamate dysfunction contribute to the pathophysiology of depression. In this review we provide an overview of how these two systems may interact. Excess levels of inflammatory mediators occur in a subgroup of depressed patients. Studies of acute experimental activation of the immune system with endotoxin and of chronic activation during interferon-α treatment show that inflammation can cause depression. Peripheral inflammation leads to microglial activation which could interfere with excitatory amino acid metabolism leading to inappropriate glutamate receptor activation. Loss of astroglia, a feature of depression, upsets the balance of anti- and pro-inflammatory mediators and further impairs the removal of excitatory amino acids. Microglia activated by excess inflammation, astroglial loss, and inappropriate glutamate receptor activation ultimately disrupt the delicate balance of neuroprotective versus neurotoxic effects in the brain, potentially leading to depression.